THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 20 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $9,147,000 | +2.1% | 9,665,000 | 0.0% | 0.11% | +41.0% |
| Q3 2021 | $8,963,000 | +323.8% | 9,665,000 | +302.2% | 0.08% | +85.7% |
| Q3 2020 | $2,115,000 | -9.5% | 2,403,000 | 0.0% | 0.04% | -45.5% |
| Q2 2020 | $2,338,000 | +0.8% | 2,403,000 | 0.0% | 0.08% | -16.3% |
| Q1 2020 | $2,319,000 | -79.3% | 2,403,000 | -77.8% | 0.09% | -54.9% |
| Q4 2019 | $11,230,000 | +13.2% | 10,817,000 | 0.0% | 0.20% | -25.3% |
| Q3 2019 | $9,921,000 | +6.7% | 10,817,000 | 0.0% | 0.27% | +4.2% |
| Q2 2019 | $9,300,000 | -11.5% | 10,817,000 | 0.0% | 0.26% | -35.9% |
| Q1 2019 | $10,504,000 | -6.3% | 10,817,000 | -0.5% | 0.41% | -49.1% |
| Q4 2018 | $11,207,000 | +51.0% | 10,867,000 | +72.8% | 0.80% | +202.3% |
| Q3 2018 | $7,423,000 | +510.4% | 6,289,000 | +413.8% | 0.27% | +259.5% |
| Q2 2018 | $1,216,000 | -60.1% | 1,224,000 | -59.2% | 0.07% | -67.4% |
| Q1 2018 | $3,051,000 | -20.0% | 3,000,000 | -13.7% | 0.23% | -35.5% |
| Q4 2017 | $3,812,000 | -61.2% | 3,475,000 | -56.6% | 0.35% | -55.6% |
| Q3 2017 | $9,835,000 | -23.6% | 8,000,000 | -15.8% | 0.79% | -36.6% |
| Q2 2017 | $12,867,000 | +45.2% | 9,500,000 | +35.7% | 1.25% | +51.3% |
| Q1 2017 | $8,864,000 | +29.4% | 7,000,000 | +16.7% | 0.83% | +39.8% |
| Q4 2016 | $6,851,000 | – | 6,000,000 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|